The global newborn screening market
is expected to reach USD 1.43 billion by 2022, according to a new report by
Grand View Research Inc. Increasing occurrence of congenital disorders that
lead to mental retardation or dysfunctioning body organs and the availability
of advanced screening technologies are expected to drive market growth over the
forecast period. Furthermore, the market is expected to witness a boost in
demand owing to, the presence of Federal Bodies involved in organizing
awareness and quality assurance programs to imbibe faith and decrease the
number of deaths caused due to negligence & non-screening. For instance, in
2011, the Ministry of Health, Japan recommended the use of mass spectrometry in
newborn screening and by 2014, the entire nation started utilizing it for 19
critical conditions.
View
summary of this report @ http://www.grandviewresearch.com/industry-analysis/newborn-screening-market
Further
key findings from the report suggest:
- Tandem mass spectroscopy is
expected to account for over 25% of newborn screening market share by
2022, owing to its ability to render faster diagnosis and cost
effectiveness.
- Pulse oximetry is expected to witness
gains of over 9.0% over the forecast period. Masimo’s Eve software and
Radical-7 oximeter gained CE marking in 2014 leading to a growth in demand
supported by quality assurance and better analysis.
- Dry blood spot test is expected
to witness lucrative growth over the forecast period. Free distribution of
filter paper by government is expected to boost the primary screening of
all newborns, thereby, accelerating market growth.
- Presently, 100% screening of
over 4 million neonates is carried out in the North America annually.
Encouraging efforts to prevent long term disabilities by healthcare
providers and government agencies are some vital factors influencing
regional market growth. Presence of favorable reimbursement policies
reduces the burden of treatment cost, thereby, promoting higher procedure
volumes
- Asia Pacific newborn screening
market is expected to witness the fastest growth of over 11.0% during the
forecast period. This growth is attributed to the presence of large
untapped opportunities, rising healthcare expenditure levels, increasing
disease prevalence rate, and the introduction of supportive government
initiatives.
- Some key players of this market
include Agilent Technologies Inc., AB Sciex LLC, Natus Medical Inc.,
PerkinElmer Inc., Covidien Plc, Masimo Corp., Trivitron Healthcare,
Bio-Rad Laboratories Inc. GE Healthcare and Waters Corp.
- Market participants are
constantly engaged in developing technologically advanced products in an
attempt to improve presence and ensure sustainability. PerkinElmer’s
“EnLite Neonatal TREC Kit” gained FDA approval in 2014 for the diagnosis
and treatment of Severe Combined Immunodeficiency Disease (SCID) leading
to replacement of non-approved tests in certain states of the U.S.
- Over 20 states along with the
Navajo Nation and the District of Columbia have put screening programs
into practice for the same.
Browse All Reports of
this category @ http://www.grandviewresearch.com/industry/healthcare-it
Grand
View Research has segmented the global newborn screening market on the basis of
product, technology, test type and region:
Product Outlook (Revenue, USD Million,
2012 – 2022)
- Instruments
- Reagents & Assay Kits
Technology Outlook (Revenue, USD
Million, 2012 – 2022)
- Tandem Mass Spectrometry
- Pulse Oximetry
- Enzyme Based Assays
- DNA Assays
- Electrophoresis
Test Outlook (Revenue, USD Million,
2012 – 2022)
- Dry Blood Spot Test
- Critical Congenital Heart
Disease (CCHD)
- Hearing Screen
Regional Outlook (Revenue, USD
Million, 2012 – 2022)
- North America
- Europe
- UK
- Germany
- France
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa (MEA)
- South Africa
- Rest of Middle East and Africa
About Grand View
Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry
James
Corporate
Sales Specialist, U.S.A.
Grand
View Research, Inc.
United
States
Phone: 1-415-349-0058
Toll
Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Website: Grand View Research
Blog
Site: http://www.divog.org/